Entelos Announces Agreement with Lilly

    


Entelos Inc.



                                  ENTELOS, Inc.

                          ("Entelos" or "the Company")

                     Entelos Announces Agreement with Lilly

Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that Eli Lilly and Company ("Lilly") has signed
an agreement with Entelos to conduct in silico research in the field of diabetes
using the Entelos(R) Metabolism PhysioLab(R) platform. Financial terms were not
disclosed.

The Entelos Metabolism PhysioLab platform is an innovative and predictive
computer model that simulates diabetic patients and can accurately predict the
effects of drugs, changes in diet and exercise, and other interventions. The
platform has already been used successfully with other pharmaceutical partners
to select targets and compounds, find the best doses for patients, and support
clinical trial design.

"We are pleased to be conducting in silico research for Lilly, who is a long
time customer of Entelos' predictive toxicology systems and other information
products," commented James Karis, President and CEO of Entelos. "We believe that
our Metabolism platform enables more rapid assessment, evaluation, and testing
of complex therapies to help accelerate R&D and we look forward to supporting
Lilly's programs."

For further information please contact:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations                          Tel: [phone]
KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson                                    Tel [phone]
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson                             Tel [phone]

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines and
health-care related consumer products are discovered, developed, and utilized.
The Company leverages its proprietary in silico disease models, "virtual
populations", and toxicology reference systems to develop safer and more
effective drugs for pharmaceutical R&D and to help improve the quality of
health-care related consumer products. Entelos provides customized technology
and research services to global pharmaceutical, health-care, and consumer
products companies in arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization,
and personal care products. The Company is also developing a model in oncology
and is collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.